Research ExplorerPublicationsClinical implications of serum neurofilament in newly diagno...

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

Standard

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. / Bittner, Stefan; Steffen, Falk; Uphaus, Timo; Muthuraman, Muthuraman; Fleischer, Vinzenz; Salmen, Anke; Luessi, Felix; Berthele, Achim; Klotz, Luisa; Meuth, Sven G; Bayas, Antonios; Paul, Friedemann; Hartung, Hans-Peter; Linker, Ralf; Heesen, Christoph; Stangel, Martin; Wildemann, Brigitte; Then Bergh, Florian; Tackenberg, Björn; Kuempfel, Tania; Weber, Frank; Zettl, Uwe K; Ziemann, Ulf; Tumani, Hayrettin; Groppa, Sergiu; Mühlau, Mark; Lukas, Carsten; Hemmer, Bernhard; Wiendl, Heinz; Gold, Ralf; Zipp, Frauke; KKNMS consortium.

In: EBIOMEDICINE, Vol. 56, 06.2020, p. 102807.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bittner, S, Steffen, F, Uphaus, T, Muthuraman, M, Fleischer, V, Salmen, A, Luessi, F, Berthele, A, Klotz, L, Meuth, SG, Bayas, A, Paul, F, Hartung, H-P, Linker, R, Heesen, C, Stangel, M, Wildemann, B, Then Bergh, F, Tackenberg, B, Kuempfel, T, Weber, F, Zettl, UK, Ziemann, U, Tumani, H, Groppa, S, Mühlau, M, Lukas, C, Hemmer, B, Wiendl, H, Gold, R, Zipp, F & KKNMS consortium 2020, 'Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study', EBIOMEDICINE, vol. 56, pp. 102807. https://doi.org/10.1016/j.ebiom.2020.102807

APA

Bittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., Meuth, S. G., Bayas, A., Paul, F., Hartung, H-P., Linker, R., Heesen, C., Stangel, M., Wildemann, B., Then Bergh, F., Tackenberg, B., ... KKNMS consortium (2020). Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBIOMEDICINE, 56, 102807. https://doi.org/10.1016/j.ebiom.2020.102807

Vancouver

Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBIOMEDICINE. 2020 Jun;56:102807. https://doi.org/10.1016/j.ebiom.2020.102807

Bibtex

@article{d55d710d98bf4e8aa672eea462c19f74,
title = "Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study",
abstract = "BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-na{\"i}ve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.",
author = "Stefan Bittner and Falk Steffen and Timo Uphaus and Muthuraman Muthuraman and Vinzenz Fleischer and Anke Salmen and Felix Luessi and Achim Berthele and Luisa Klotz and Meuth, {Sven G} and Antonios Bayas and Friedemann Paul and Hans-Peter Hartung and Ralf Linker and Christoph Heesen and Martin Stangel and Brigitte Wildemann and {Then Bergh}, Florian and Bj{\"o}rn Tackenberg and Tania Kuempfel and Frank Weber and Zettl, {Uwe K} and Ulf Ziemann and Hayrettin Tumani and Sergiu Groppa and Mark M{\"u}hlau and Carsten Lukas and Bernhard Hemmer and Heinz Wiendl and Ralf Gold and Frauke Zipp and {KKNMS consortium}",
note = "Copyright {\textcopyright} 2020 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2020",
month = jun,
doi = "10.1016/j.ebiom.2020.102807",
language = "English",
volume = "56",
pages = "102807",
journal = "EBIOMEDICINE",
issn = "2352-3964",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

AU - Bittner, Stefan

AU - Steffen, Falk

AU - Uphaus, Timo

AU - Muthuraman, Muthuraman

AU - Fleischer, Vinzenz

AU - Salmen, Anke

AU - Luessi, Felix

AU - Berthele, Achim

AU - Klotz, Luisa

AU - Meuth, Sven G

AU - Bayas, Antonios

AU - Paul, Friedemann

AU - Hartung, Hans-Peter

AU - Linker, Ralf

AU - Heesen, Christoph

AU - Stangel, Martin

AU - Wildemann, Brigitte

AU - Then Bergh, Florian

AU - Tackenberg, Björn

AU - Kuempfel, Tania

AU - Weber, Frank

AU - Zettl, Uwe K

AU - Ziemann, Ulf

AU - Tumani, Hayrettin

AU - Groppa, Sergiu

AU - Mühlau, Mark

AU - Lukas, Carsten

AU - Hemmer, Bernhard

AU - Wiendl, Heinz

AU - Gold, Ralf

AU - Zipp, Frauke

AU - KKNMS consortium

N1 - Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2020/6

Y1 - 2020/6

N2 - BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.

AB - BACKGROUND: We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.METHODS: In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.FINDINGS: Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.INTERPRETATION: Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.FUNDING: Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.

U2 - 10.1016/j.ebiom.2020.102807

DO - 10.1016/j.ebiom.2020.102807

M3 - SCORING: Journal article

C2 - 32460167

VL - 56

SP - 102807

JO - EBIOMEDICINE

JF - EBIOMEDICINE

SN - 2352-3964

ER -